Last reviewed · How we verify
NCT02881931
FuRST 2.0 Cognitive Pre-Testing
trial testing FuRST 2.0 in Huntington's Disease in 75 participants. Completed in 28 July 2017.
28 July 2017
Quick facts
| Lead sponsor | CHDI Foundation, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 28 February 2017 |
| Primary completion | 28 July 2017 |
| Estimated completion | 28 July 2017 |
| Sites | 4 locations across Canada, United States |
Drugs / interventions tested
- FuRST 2.0
Conditions studied
- Huntington's Disease — all drugs for Huntington's Disease →
Sponsor
CHDI Foundation, Inc.
Who can join
18 and older, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The FuRST 2.0 scale is being developed as a Patient Reported Outcome (PRO) with information coming directly from the Huntington's Disease Gene Expansion Carrier (HDGEC) and companion through self-report. The purpose of this study is to identify real or potential comprehension or usage problems with questionnaire items or response options. Through a process of structured cognitive de-briefing with HDGEC participants and companions, independently, followed by qualitative analysis, the final phrasing of the individual items and response options for the scale will be generated. Depending on the results of the first round of cognitive pre-testing, additional rounds of cognitive pre-testing may be required.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02881931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of FuRST 2.0
Trials testing the same drug.
- NCT03709173 — FuRST 2.0 Cognitive Pre-testing - Round 2 · completed
Other recruiting trials for Huntington's Disease
Currently open trials in the same condition.
- NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
- NCT06585449 — A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease · Phase 1 · recruiting
- NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting
Other CHDI Foundation, Inc. trials
Trials by the same sponsor.
- NCT03810898 — iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626 · EARLY_PHASE1 · terminated
- NCT03628235 — HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States · completed
- NCT03709173 — FuRST 2.0 Cognitive Pre-testing - Round 2 · completed
- NCT02956148 — Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02881931 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CHDI Foundation, Inc.
- Last refreshed: 8 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02881931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing